key: cord-0780156-0ya182lo
authors: Shah, Melisa M; Rasheed, Mohammad Ata Ur; Harcourt, Jennifer L; Abedi, Glen R; Stumpf, Megan M; Kirking, Hannah L; Tamin, Azaibi; Mills, Lisa; Armstrong, Madeleine; Salvatore, Phillip P; Surasi, Krishna; Scott, Sarah E; Killerby, Marie E; Briggs-Hagen, Melissa; Saydah, Sharon; Tate, Jacqueline E; Fry, Alicia M; Hall, Aron J; Thornburg, Natalie J; Midgley, Claire M
title: Twelve-month Follow-up of Early COVID-19 Cases in the United States: Cellular and Humoral Immune Longevity
date: 2022-01-05
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab664
sha: 62fd50a09057e0a75f1ea5ed2aecd368fca4c493
doc_id: 780156
cord_uid: 0ya182lo

We quantify antibody and memory B cell responses to SARS-CoV-2 at 6- and 12-months post-infection among 7 unvaccinated U.S. COVID-19 cases. All had detectable S-specific memory B cells and IgG at both time points, with geometric mean titers of 117.2 BAU/ml and 84.0 BAU/ml at 6 and 12 months, respectively.

M a n u s c r i p t 3 , and protection from reinfection is high in the first 6-9 months after infection. 4, 5 We characterize antibody and memory B cell responses to SARS-CoV-2 infection at 12 months post-onset among early U.S. COVID-19 cases. 6, 7 Additionally, we describe immunologic trends in an individual with possible reinfection 10.5 months after initial infection. As one of the earliest detailed description of SARS-CoV-2-specific immune responses at 12 months, this investigation provides further insight into the natural history of SARS-CoV-2.

Among the first 14 detected COVID-19 cases in the U.S. who previously underwent specimen collection and interviews during acute illness or at 6-months post illness onset 6,7 , 7 were included in this follow-up investigation at 12 months (+/-2 weeks). These 7 participants underwent a semi-structured interview about their health, healthcare use, COVID-19 tests, possible exposures, and vaccination status since the investigation 6 months prior. 7 Blood was collected for antibody and memory B cell assessment.

Plasma specimens from the 12-month investigation were assessed for neutralizing antibodies and S-specific IgG, IgM, and IgA by in-house ELISAs, as previously described. 6, 7 Plasma specimens from all available acute and convalescent time points were also analyzed at 1:100 and 1:5000 dilutions for IgG and IgM to SARS-CoV-2 nucleocapsid (N), receptor binding domain (RBD), and S protein (V-PLEX SARS-CoV-2 Panel 2 Kit, Meso Scale Discovery (MSD)). PBMCs collected at the 6-and 12-month investigation were used to A c c e p t e d M a n u s c r i p t 5 assess S-specific IgG and IgA memory B cell responses. PBMC stimulation was performed as previously described. 8, 9 One residual SARS-CoV-2 RNA-positive nasal specimen that had been collected at a community testing site was submitted to CDC for confirmatory virologic testing. RT-PCR, virus culture, and whole genome sequencing were performed as previously described. 6 Additional laboratory methods are available in the Supplemental Information.

Interviews were conducted and blood was collected from 7 early U.S. COVID-19 cases at 12 months post-onset, during January 2021. As reported at the acute illness 6 , 2 (B, G) reported underlying co-morbidities, and 2 (B, F) required supplemental oxygen without mechanical ventilation (Supp. Table 1 ). At the time of the 12-month investigation, none of the seven participants had received a COVID-19 vaccination, and none reported close contact with a known COVID-19 case since their initial illness.

One participant (K) reported a positive SARS-CoV-2 test in December 2020, approximately 10.5 months after onset of initial illness. As previously reported 6 A c c e p t e d M a n u s c r i p t 6 Additional antibody data, across the time course of infection, were collected using a standardized multiplex assessment of S-, RBD-and N-specific IgG (Fig. 1) and IgM (Supp. infection. 2 In our study, all seven participants retained detectable S-specific IgG in the blood at 12 months post-onset, and only 4/7 participants had detectable N-specific IgG. N-specific waning was greater than S-specific waning as previously reported 10 , though lack of detection could be related to lower assay sensitivity. As time since infection passes, N-specific assays may become a less sensitive marker of prior infection. S-specific IgG correlates for 80% and 50% vaccine effectiveness (VE) against symptomatic COVID-19 for the ChAdOx1 nCoV-19 (AZD1222) 11 and 90% VE against symptomatic COVID-19 for mRNA-1273 (Moderna) 12, 13 were recently reported. VE against severe disease is likely higher at these antibody levels. 14 Among our 7 participants, none had S-specific IgG at levels above the 80% VE correlate (264 BAU/ml) for ChAdOx1 nCoV-19 or 90% VE correlate (298 BAU/ml) to mRNA-1273 at either 6 or 12 months post-onset. However, 6 of 7 participants, including Participant K, had levels above the 50% VE correlate (29 BAU/ml) for ChAdOx1 nCoV-19 at 6 and 12 months post-onset. 11 The implications of these comparisons for infection-induced protection from reinfection are not yet fully understood.

As residual serum antibodies wane over time, memory B cells become an increasingly critical component of the immune response, facilitating rapid production of new antibodies upon reinfection to attenuate virus replication and possibly illness severity. We detected S-specific IgG memory B cells in all participants and IgA memory B cells in 6 of 7 participants at 12 months post-onset, exhibiting similar levels to those reported after influenza virus infection. 9 In previous reports, SARS-CoV-2-specific memory B cells were stable up to 6 months post-infection. 3 Understanding the complexities of B and T cell responses to SARS-CoV-2 will be crucial to identifying immunologic correlates of viral clearance and protection against reinfection. (approximately one month after reinfection), participant K did not have detectable neutralizing antibodies, and did not exhibit detectable serum IgG or IgA boosting; however, S-specific IgA-producing memory B cells, which were not detectable at 6 months, were detectable at 12 months. These findings may reflect a limited mucosal immune response following reinfection or simply the heterogenous nature of infection-acquired immune responses.

Generalizations from this investigation are limited by the small sample size.

Infections occurred early in the pandemic, and data reflect immune responses to early SARS-CoV-2 strains. Routine screening for SARS-CoV-2 reinfection among participants was not systematically available and reinfections could have been missed. Cellular analyses were performed on previously frozen PBMCs, which may have been less sensitive than using freshly isolated PBMCs. Variant-specific immunologic assays were not available in this study. Additionally, measures of T cell responses and mucosal antibodies were not included but may play an important role in immune memory and protection against SARS-CoV-2 reinfection.

We demonstrate detection of S-specific IgG and memory B cells at one year after SARS-CoV-2 infection and describe humoral and cellular responses before and one month after a single reinfection case. Additional studies are needed to further characterize the correlation of B and T cells with protection against reinfection, and to better assess the duration of protection conferred by infection alone or in conjunction with vaccination.

A c c e p t e d M a n u s c r i p t 9 Figure 1 : S-, RBD-and N-specific IgG a responses up to 12 months after COVID-19 illness onset among early US COVID-19 cases. Asterisks indicate the patient received supplemental oxygen during their acute COVID-19 illness. Dashed lines indicate the threshold of detection for each assay. a Spike-specific IgG titers from the acute time points (<45 days) and 6-month time points were previously published using a different assay 7 ; specimens were retested using the V-PLEX SARS-CoV-2 Panel 2 Kit (Meso Scale Discovery) assay for standardized comparisons in this analysis. 

Humoral Immune Response to SARS-CoV-2 in Iceland

A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinicalMedicine

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Shedding of Culturable Virus, Seroconversion, and 6-Month Follow-up Antibody Responses in the First 14 Confirmed Cases of Coronavirus Disease 2019 in the United States

Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system

Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood

Evolution of immune responses to SARS-CoV-2 in mildmoderate COVID-19

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

A Population-Based Threshold of Protection for COVID-19 Vaccines. Preprint (Version 1) Available at Research Square

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t